Luveltamab Tazevibulin is a monoclonal antibody conjugated commercialized by Sutro Biopharma, with a leading Phase III program in Epithelial Ovarian Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Luveltamab Tazevibulin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Luveltamab Tazevibulin is expected to reach an annual total of $257 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Luveltamab Tazevibulin Overview
STRO-002 is under development for the treatment of solid tumors, relapsed/refractory cancers like epithelial ovarian cancer, endometrial carcinoma, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer, triple negative breast cancer, adenocarcinoma and relapsed/refractory rare pediatric acute myeloid leukemia (AML). It is administered through intravenous route. It is developed based on Xpress CF plus platform technology. The drug candidate is a potent and Sutro proprietary hemia-sterlin derivative warhead. It is a monoclonal antibody conjugate that acts by targeting folate receptor alpha (FolR alpha).
Sutro Biopharma Overview
Sutro Biopharma is a clinical-stage oncology company that carries out the discovery and development of cancer therapeutics. The company provides antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immune-oncology therapies and vaccines through its XpressCF and XpressCF+ platforms. The company’s product pipeline includes STRO-002 and luvelta targeting ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer and GLlS2 pediatric acute myeloid leukemia; and STRO-004 for solid tumors. It is also developing partner programs such as VAX-24 and VAX-31 for invasive pneumococcal disease; MK-1484 which treats metastatic solid tumors; and STRO-003 targeting solid tumor and hematological cancers. It works in collaboration with pharmaceutical and biotechnology companies such as Merck & Co. Inc. and Astellas Pharma Inc. Sutro Biopharma is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$153.7 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$67.8 million in FY2022. The operating loss of the company was US$89.3 million in FY2023, compared to an operating loss of US$128.9 million in FY2022. The net loss of the company was US$106.8 million in FY2023, compared to a net loss of US$119.2 million in FY2022.
For a complete picture of Luveltamab Tazevibulin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
